Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

Will Resubmit With New Data from Ongoing Studies

CAMBRIDGE, Mass., March 19 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced the withdrawal of the European application to extend the Evoltra(R) (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year.

In a letter to the European Medicines Agency (EMEA) on behalf of Bioenvision, Genzyme states that the withdrawal is based on the EMEA's Committee for Medicinal Products for Human Use (CHMP) assessment that the data from the BIOV121 study are not sufficient to support a recommendation for market approval at this time. Bioenvision is now a wholly-owned subsidiary of Genzyme.

"As we expected, the filing that Bioenvision submitted to the EMEA was not sufficient to support approval in adult AML and our subsequent conversations with the CHMP have confirmed this assessment," stated Mark J. Enyedy, president of Genzyme Oncology, a business unit of Genzyme Corp. "We have engaged in a positive dialogue with the Rapporteurs regarding the requirements for approval and will develop a new submission to include data from one or more ongoing clinical studies of clofarabine in this patient population for submission possibly as early as the fourth quarter of this year."

In the United States, Genzyme has completed enrollment for a pivotal study in previously untreated, older adult patients with AML who are unlikely to benefit from standard intensive induction chemotherapy. Data from this study, known as CLASSIC II, are expected to provide substantial evidence for expa
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
Breaking Biology Technology:In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... DIEGO, Aug. 21 NovaRx Corporation announced ... III clinical trial of,Lucanix(R) (belagenpumatucel-L) in the ... The first patient enrolled in the study ... principal investigator at the University,of California, San ...
... Arpida Ltd.,(SWX: ARPN) today announced that the ... its Marketing Authorisation Application (MAA) for,intravenous iclaprim. ... in,the European Union for the treatment of ... is a hospital antibiotic drug candidate with,potent ...
... iron are the basis for much of mankind,s technology, ... this week,s issue of the journal Nature ... and industrial researchers from the UK, USA and Lesotho, ... small amount of another common metal, manganese, to create ...
Cached Biology Technology:NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 2NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 3NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 4Arpida's iclaprim MAA Accepted for Review by EMEA 2Arpida's iclaprim MAA Accepted for Review by EMEA 3Creating unconventional metals 2
(Date:10/31/2014)... out of a nagging mystery about the development of animal ... why animal species didn,t flourish sooner, once sufficient oxygen covered ... of the Proterozoic period, about 800 million years ago — ... researchers think there also was plenty of oxygen? , Well, ... , In a study published Oct. 30 in Science ...
(Date:10/31/2014)... green space in cities is good for attracting species, but ... environments, a University of Iowa study has found. , The ... in Iowa, and recorded the abundance of two insects that ... of the trees, black cherry and black walnut, they didn,t ... fruit flies that feed on the walnuts and black cherries ...
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2Green spaces don't ensure biodiversity in urban areas 2A matter of life and death: Cell death proteins key to fighting disease 2
... are developing a cost-effective electronic monitoring system that will ... ecosystems by allowing users to track water-quality data from ... a National Science Foundation (NSF) grant. "Our goal ... environmental conditions in the Chesapeake Bay, the sounds of ...
... to help the government cut through red tape and roll ... This week, the university,s Durham Energy ... meet with the Department of Energy & Climate Change to ... on Wednesday November 3rd will also be attended by Ofgem ...
... Calif., Nov. 1, 2010 General Manifolds LLC, a ... that the United States Patent and Trademark Office has ... method for simulating functions within the cerebral cortex of ... a broad range of applications from artificial intelligence to ...
Cached Biology News:Researchers developing real-time electronic monitoring for coastal waters 2Durham Energy Institute to advise government on green technology 2General Manifolds LLC Announces Issuance of US Patent in Computational Neuroscience 2
... Service The Human Genetic Cell Bank ... (EBV) immortalisation of human peripheral blood lymphocytes ... cell lines (LCLs). These cell lines are ... source of genomic DNA and RNA. ...
... Extract Protein Array Kit is designed for ... The expression of a protein in an ... antibody. When the antibody binds the protein, ... chemiluminescent or fluorescent signal created by directly ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
... is specifically formulated for mounting tissue specimens, ... stained with immunohistochemical methods for viewing by ... with chromogens, such as AEC, that are ... dries completely when slides are cover-slipped forming ...
Biology Products: